Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
Among cisplatin-ineligible patients with MIBC, nivolumab alone was well tolerated. Ipilimumab/nivolumab caused toxicity that delayed cystectomy. Cases of progression before cystectomy indicated insufficient efficacy of pure neoadjuvant immunotherapy for unselected patients. Despite low response rates, some patients experienced sustained clinical CRs without cystectomy.
Authors
- Allison L. Richards (ORCID: https://orcid.org/0000-0003-2312-2302)
- Guido Dalbagni
- Samuel A. Funt (ORCID: https://orcid.org/0000-0002-7235-6319)
- Timothy F. Donahue (ORCID: https://orcid.org/0000-0003-1855-1794)
- Eugene J. Pietzak (ORCID: https://orcid.org/0000-0002-5121-5701)
- Scot A. Niglio (ORCID: https://orcid.org/0000-0002-1421-1533)
- Irina Ostrovnaya (ORCID: https://orcid.org/0000-0003-1783-0070)
- P Wong
- Gopa Iyer
- David H. Aggen (ORCID: https://orcid.org/0000-0003-3963-5751)
- Brendan J. Guercio (ORCID: https://orcid.org/0000-0001-6296-2473)
- A Goh
- Vignesh Ravichandran (ORCID: https://orcid.org/0000-0002-1532-2593)
- Cassidy C. Cobbs (ORCID: https://orcid.org/0000-0003-4465-8894)
- Vanessa Peters
- Jie-Fu Chen
- S. Machele. Donat
- Ronak H. Shah
- Bernard H. Bochner
- Min Yuen Teo
- Eugene K. Cha
- Ashley M. Regazzi
- Jonathan E. Rosenberg
- Mark T. A. Donoghue
- Hikmat A. Al-Ahmadie
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Cornell University (US)
- Beaumont Hospital (IE)
- University of Rochester (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-02-02
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-3771
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Conquer Cancer Foundation
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- Bladder Cancer Advocacy Network
- Exelixis
- UroGen Pharma
- Astellas Pharma
- National Institutes of Health
- Genentech
- Chugai Pharmaceutical
- National Cancer Institute